Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study supports possible role of urate in slowing Parkinson's disease progression

14.10.2009
Results confirm those of 2008 study, clinical trial is underway

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and Harvard School of Public Health (HSPH), has found evidence supporting the findings of their 2008 study – that elevated levels of the antioxidant urate may slow the progression of Parkinson's disease.

The report – which will appear in the December 2009 Archives of Neurology and has been released online – analyzed blood and cerebrospinal fluid samples from participants in a 1980s trail of potential Parkinson's medications, confirming the previous study's findings in a totally different group of patients.

"These results were critically important. Only now we can be reasonably sure that the slower rate of progression in patients with higher concentrations of urate is real and not a chance occurrence," says Alberto Ascherio, MD, DrPh, of HSPH, the new study's lead author.

Parkinson's disease – characterized by tremors, rigidity, difficulty walking and other symptoms – is caused by destruction of brain cells that produce the neurotransmitter dopamine. The 2008 study, which investigated the observation that healthy people with elevated but still normal urate levels have a reduced risk of developing Parkinson's, found an association between higher blood urate levels and slower disease progression in 800 participants from a previous clinical trial.

To follow up that finding, the current study reviewed information from a much earlier trial that had investigated whether the drug deprenyl, now an established treatment for Parkinson's, or doses of vitamin E would slow disease progression. The researchers analyzed samples of both blood and cerebrospinal fluid from 800 participants in the DATATOP study, conducted by the Parkinson's Study Group at centers across the U.S. and Canada, to find any association of urate levels with how quickly recently diagnosed patients progressed to the point where they needed to begin standard drug therapy.

Confirming the results of the 2008 study, they found that participants with the highest blood urate levels had a 36 percent less chance of needing to begin treatment during the two-year study period than did those with the lowest urate levels. Similar results were seen for urate levels in the cerebrospinal fluid. Also echoing last year's results, the association of urate levels with risk was robust in men but less clear in women, which may reflect the fact that few women have the high natural urate levels associated with risk reduction.

"Since cerebrospinal fluid circulates in and around the brain, the association with urate CSF levels strengthens the possibility that urate has a protective influence on the cells that degenerate in Parkinson's disease," says Michael Schwarzschild, MD, PhD, of MGH-MIND, the study's senior author. "Urate is a major antioxidant and it can protect brain cells in the lab, which makes this a compelling possibility; but we don't yet know if it's urate itself or some urate-determining factor that helps people with Parkinson's."

One unexpected observation was that the association of urate levels with disease progression was not seen in DATATOP trial participants who had received vitamin E, also a powerful antioxidant that had no effect on disease progression in the original study. The researchers speculate that vitamin E might block urate's effects or that the elevated doses in the DATATOP trial might have had a pro-oxidant effect, possibilities that need further investigation.

With the support of the Michael J. Fox Foundation, Schwarzschild and Ascherio, along with Parkinson Study Group colleagues from across the country, are conducting a multicenter Phase 2 trial at 10 centers. Enrolling 90 recently diagnosed patients, the SURE-PD trial will investigate whether treatment with the urate precursor inosine can safely increase urate levels with a goal of slowing disease progression. More information on this trial is available at http://www.pdtrials.org/en/browse/all/view/259.

"Because elevated urate levels have known health risks, including gout and kidney stones," Schwarzschild stresses, "urate elevation should only be attempted in the context of a closely monitored clinical trial in which potential benefits and risks are carefully balanced."

The current study was supported by grants from the National Institutes of Health, the Department of Defense, the RJG Foundation, the American Federation for Aging Research, the Parkinson Disease Foundation and the Parkinson Study Group. Co-authors of the Archives of Neurology paper are Kui Xu, MD, and Marsha Tennis, RN, MGH-MIND; Wayne Matson, PhD, and Mikhail Bogdanov, PhD, Veterans Administration Medical Center, Bedford, Mass.: Peter LeWitt, MD, Wayne State University School of Medicine, Detroit; Shirley Eberly, MS, Arthur Watts, Karl Keiburtz, MD, Alice Rudolph, PhD, Steven Schwid, MD, David Oakes, PhD, and Ira Shoulson, MD, University of Rochester; M. Flint Beal, MD, Cornell University; Stanley Fahn, MD, Columbia University; Connie Marras, MD, and Anthony Lang, MD, University of Toronto, and Caroline Tanner, MD, PhD, Parkinson's Institute, Sunnyvale, Calif.

Massachusetts General Hospital (www.massgeneral.org), established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of $550 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Sue McGreevey | EurekAlert!
Further information:
http://www.massgeneral.org

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>